Skip to main content

Pertussis

7
Pipeline Programs
9
Companies
13
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
2
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
6100%
+ 9 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

BioNet Asia
BioNet AsiaThailand - Bangkok
3 programs
1
1
Pertagen® vaccinePhase 4Vaccine1 trial
Pertagen® aP + Td-pur®Phase 21 trial
Biological/Vaccine: PertagenN/AVaccine1 trial
Active Trials
NCT04529720Completed159Est. Nov 2021
NCT02946190Completed60Est. Mar 2017
NCT06803524Recruiting126Est. Mar 2026
ILIAD Biotechnologies
1 program
1
BPZE1 pertussis vaccine and VaxINatorPhase 2Vaccine1 trial
Active Trials
NCT03942406Completed300Est. Jun 2020
Sandoz
SandozAustria - Kundl
2 programs
2
Acellular pertussis vaccinePhase 1Vaccine1 trial
aP boosterPhase 11 trial
Active Trials
NCT01529645Completed420Est. Jul 2013
NCT02382913Completed315Est. Jun 2015
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
BPZE1Phase 11 trial
Active Trials
NCT01188512Completed48Est. Jan 2012
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
Bordetella pertussis D420Phase 11 trial
Active Trials
NCT05136599Completed79Est. Mar 2025
Sanofi
SanofiPARIS, France
3 programs
Pentacel®N/A2 trials
DTaP-IPV combined vaccinePHASE_3Vaccine1 trial
Adacel®PHASE_41 trial
Active Trials
NCT01129362Completed1,195Est. Dec 2014
NCT00772369Completed3,214Est. Apr 2005
NCT00319852Completed442Est. Jul 2008
+1 more trials
Novartis
NovartisBASEL, Switzerland
2 programs
Acellular pertussis vaccinePHASE_1Vaccine
aP boosterPHASE_1
GSK
GSKLONDON, United Kingdom
1 program
Data collectionN/A1 trial
Active Trials
NCT02096276Completed1,517Est. Aug 2019
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
Data collectionN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BioNet AsiaPertagen® vaccine
SanofiAdacel®
SanofiDTaP-IPV combined vaccine
ILIAD BiotechnologiesBPZE1 pertussis vaccine and VaxINator
BioNet AsiaPertagen® aP + Td-pur®
Allergy TherapeuticsBordetella pertussis D420
SandozaP booster
SandozAcellular pertussis vaccine
UNION therapeuticsBPZE1
BioNet AsiaBiological/Vaccine: Pertagen
GSKData collection
SanofiPentacel®
SanofiPentacel®

Clinical Trials (13)

Total enrollment: 7,885 patients across 13 trials

NCT06803524BioNet AsiaPertagen® vaccine

10-year Follow-up After a Single Dose Acellular Pertussis Vaccination

Start: May 2025Est. completion: Mar 2026126 patients
Phase 4Recruiting
NCT04543669SanofiAdacel®

Adacel® Booster Vaccination for CMI Assay Development

Start: Jul 2017Est. completion: Sep 201710 patients
Phase 4Completed
NCT00319852SanofiDTaP-IPV combined vaccine

Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV

Start: Apr 2006Est. completion: Jul 2008442 patients
Phase 3Completed
NCT03942406ILIAD BiotechnologiesBPZE1 pertussis vaccine and VaxINator

Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults

Start: Jun 2019Est. completion: Jun 2020300 patients
Phase 2Completed
NCT02946190BioNet AsiaPertagen® aP + Td-pur®

The PertADO Geneva Trial

Start: Oct 2016Est. completion: Mar 201760 patients
Phase 2Completed
NCT05136599Allergy TherapeuticsBordetella pertussis D420

Establishing a Controlled Human Infection Model of Bordetella Pertussis

Start: Jan 2022Est. completion: Mar 202579 patients
Phase 1Completed
NCT02382913SandozaP booster

Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)

Start: Apr 2015Est. completion: Jun 2015315 patients
Phase 1Completed
NCT01529645SandozAcellular pertussis vaccine

Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years

Start: Mar 2012Est. completion: Jul 2013420 patients
Phase 1Completed
NCT01188512UNION therapeuticsBPZE1

First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine

Start: Aug 2010Est. completion: Jan 201248 patients
Phase 1Completed
NCT04529720BioNet AsiaBiological/Vaccine: Pertagen

5-year Follow-up After a Single Dose Acellular Pertussis Vaccination

Start: Aug 2020Est. completion: Nov 2021159 patients
N/ACompleted
NCT02096276GSKData collection

Boostrix® Pregnancy Registry

Start: Mar 2014Est. completion: Aug 20191,517 patients
N/ACompleted
NCT01129362SanofiPentacel®

Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines

Start: Feb 2010Est. completion: Dec 20141,195 patients
N/ACompleted
NCT00772369SanofiPentacel®

Retrospective Survey of Safety of Fourth Dose Pentacel® in Children

Start: Sep 2003Est. completion: Apr 20053,214 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 7,885 patients
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.